[Possibility of predicting the use of doxazosin in the treatment of arterial hypertension].
Fifteen patients with arterial hypertension (AH) were examined. Their peripheral venous hemodynamics, central circulation, systolic and diastolic functions were studied and a course therapy with doxazosin (cardura, Pfizer, USA) was performed for 30 days. Cardura (doxazosin) was found to be the drug of choice for antihypertensive therapy in patients with AH concurrent with baseline systemic venous normo- or hypertension. In patients with baseline venous hypervolemia in the presence of venous hypotension, cardura therapy resulted in deterioration of signs of venous insufficiency and promoted the development (in 38% of the cases) or progression (in 38%) of diastolic dysfunction of the left ventricle (LV). Thus, the venous circulation and LV myocardial function should be originally assessed in order to decide whether cardura (doxazosin) is used in antihypertensive therapy in patients with AH.
Khlynova
O V
OV
Tuev
A V
AV
Agafonov
A V
AV
Shkliaeva
L N
LN
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D017292:Doxazosin / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin